Drug Trial Radar · NCT07710664
A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Newish Biotech (Wuxi) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-center, investigator-initiated exploratory trial evaluating NWRD09 in 10 participants with persistent HPV16 infection in the anal region.
Conditions
- Persistent HPV16 Infection
Interventions
NWRD09Drug
Each participant will be administered NWRD09 by IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of local and systemic adverse events (AEs).Time frame: Up to 28 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.